Program
vadadustat
Also written as “Vadadustat”, “AKB-6548” and “MT-6548”.
Its studies are mostly in Anemia · Renal Insufficiency, Chronic, led by 2 companies.
Drug pageVadadustat: every studyAll 40 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akebia Therapeutics | 320 open or running | phase 3since Jan 4, 2016 | Nov 5, 2010 | none ahead |
| Tanabe Pharmaits history only | 40 open or running | phase 3since Oct 30, 2017 | Oct 30, 2017 | none ahead |
Also a collaborator on its studies: Otsuka.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Akebia Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 12 earlier studies, Nov 5, 2010 to Sep 2, 2016.
- Dec 9, 2015Named vadadustatINNProposed as its International Nonproprietary Name in WHO's List 114 · before, AKB-6548, MT-6548
- Feb 13, 20172 phase 2 studies in AnemiaNCT03054350, NCT03054337
- May 3, 2017Phase 2 study in AnemiaNCT03140722 · 2 enrolled · United States
- Aug 4, 2017Phase 3 study in AnemiaNCT03242967 · United States
- Jun 12, 2018Phase 1 study in HealthyNCT03639155 · 50 enrolled · United States
- Aug 31, 2018Phase 1 study in HealthyNCT03657290 · 54 enrolled · United States
- Dec 3, 2018Phase 2 study in AnemiaNCT03799627 · 175 enrolled · United States
- Dec 27, 20185 phase 1 studiesNCT03801759, NCT03801746, NCT03801733 and 2 more
- Jun 18, 2019Phase 1 study in AnemiaNCT03992066 · 46 enrolled · United States
- Mar 5, 2020Phase 1 study in Healthy VolunteersNCT04299633 · 54 enrolled · Canada
- Mar 16, 2020Phase 3 study in AnemiaNCT04313153 · 319 enrolled · United States, Czechia, Hungary and more
- Nov 2, 2020Phase 2 study in Renal Insufficiency, ChronicNCT04707573 · 22 enrolled · United States
- Jan 12, 2021Phase 3 study in AnemiaNCT04707768 · 456 enrolled · United States
- Sep 28, 20212 phase 3 studies in AnemiaNCT05082584, NCT05082571
- Mar 27, 2025Phase 3 study in Renal Insufficiency, ChronicNCT06901505 · 353 enrolled · United States
TargetBeta
“Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| roxadustatrule | Astellas Pharma | phase 4 | 47 |
| daprodustatrule | GlaxoSmithKline | phase 3 | 33 |
Studies
All 32 Akebia Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06901505Renal Insufficiency, Chronic · United States | 3 | Completed | Aug 12, 2026 | 353 |
| NCT05082584Anemia · United States | 3 | Withdrawn | Jul 2026 | 0 |
| NCT05082571Anemia · United States | 3 | Withdrawn | Jul 2026 | 0 |
| NCT04707768Anemia · United States | 3 | Completed | Jan 6, 2023 | 456 |
| NCT04707573Renal Insufficiency, Chronic · United States | 2 | Completed | Sep 24, 2010 | 22 |
| NCT04313153Anemia · United States, Czechia, Hungary and more | 3 | Completed | Nov 26, 2021 | 319 |
| NCT04299633Healthy Volunteers · Canada | 1 | Completed | Aug 2, 2020 | 54 |
| NCT03992066Anemia · United States | 1 | Completed | May 5, 2020 | 46 |
| NCT03801759Drug Interaction Potentiation · Canada | 1 | Completed | Sep 30, 2018 | 62 |
| NCT03801746Drug Interaction Potentiation · Canada | 1 | Completed | Aug 15, 2018 | 40 |
| NCT03801733Drug Interaction Potentiation · Canada | 1 | Completed | Nov 24, 2018 | 134 |
| NCT03799848Hepatic Impairment · United States | 1 | Completed | Oct 18, 2018 | 24 |
| NCT03789032Drug Interaction Potentiation · Canada | 1 | Completed | Nov 9, 2018 | 20 |
| NCT03799627Anemia · United States | 2 | Completed | Jun 5, 2020 | 175 |
| NCT03657290Healthy · United States | 1 | Completed | Oct 16, 2018 | 54 |
| NCT03639155Healthy · United States | 1 | Completed | May 23, 2018 | 50 |
| NCT03242967Anemia · United States | 3 | Withdrawn | Feb 12, 2018 | 0 |
| NCT03140722Anemia · United States | 2 | Terminated | Mar 21, 2018 | 2 |
| NCT03054350Anemia · Japan | 2 | Completed | Oct 24, 2017 | 60 |
| NCT03054337Anemia · Japan | 2 | Completed | Jul 4, 2017 | 51 |
| NCT02892149Anemia · United States, Argentina, Australia and more | 3 | Completed | Jan 16, 2020 | 3,554 |
| NCT02865850Anemia · United States, Argentina, Brazil and more | 3 | Completed | Jan 31, 2020 | 369 |
| NCT02680574Anemia · United States, Argentina, Australia and more | 3 | Completed | Jun 18, 2020 | 1,725 |
| NCT02648347Anemia · United States, Argentina, Australia and more | 3 | Completed | Jun 4, 2020 | 1,751 |
| NCT02502500Healthy Volunteers | 1 | Completed | Jul 2015 | 12 |
| NCT02412449Anemia · United States | 1 | Completed | Apr 2015 | 18 |
| NCT02327546Anemia · United States | 1 | Completed | Dec 2014 | 10 |
| NCT02260193Anemia · United States | 2 | Completed | Jul 22, 2015 | 94 |
| NCT02062203Anemia · United States | 1 | Completed | Apr 2014 | 50 |
| NCT01906489Anemia · United States | 2 | Completed | Sep 3, 2014 | 210 |
| NCT01381094Anemia · United States | 2 | Completed | Feb 16, 2012 | 93 |
| NCT01235936Anemia · United States | 2 | Completed | Apr 13, 2011 | 10 |
How it is read
Names in the registry
- “Vadadustat”, 19 entries
- “AKB-6548”, 8 entries
- “MT-6548”, 4 entries
- “vadadustat”, 4 entries
- “vadadustat reference tablets”, 1 entry
Conditions, from the studies’ own filings
- Anemia, 25 studies
- Renal Insufficiency, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.